However, all patients ultimately progress after this therapy, and there are no standard second-line options. The ABC-02 trial established benefit of gemcitabine and cisplatin as standard of care for first-line chemotherapy in fit patients. ![]() Unfortunately, development in cholangiocarcinoma has remained limited. There has been rapid progress in the fields of targeted and immunotherapy in solid tumors. I hope to progress the field in partnership with a basic scientist to evaluate innovative treatments for our patients. My overarching career goal is to identify and develop novel therapeutic strategies to improve clinical outcomes for patients with cholangiocarcinoma and pancreatic cancers. Diversity in Cancer Research Post-Baccalaureate Program.Community-Academic Collaborative Pilot Research Award.Cancer Drug Discovery and Development Accelerator.Research Program Support for Pilot Projects.Preclinical Modeling & Therapeutics Core. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |